Table 1 Clinical and pathological characters for patients with metastatic GIST who received R0/1 or R2 CRS
Parameters | n | R0/1 Resection | R2 Resection | P-value |
|---|---|---|---|---|
Age (y) | 52.90 ± 8.556 | 57.20 ± 4.970 | 0.164 | |
Operative time (min) | 326.40 ± 115.64 | 350.40 ± 120.34 | 0.902 | |
Blood loss (ml) | 1210.00 ± 1567.34 | 700.00 ± 538.52 | 0.180 | |
Gender | 0.680 | |||
Male | 11 (73.4%) | 7 (46.7%) | 4 (26.7%) | |
Female | 4 (26.7%) | 3 (31.9%) | 1 (6.7%) | |
Tumor size (cm) | 13.77 ± 8.67 | 14.80 ± 7.29 | 0.489 | |
Primary tumor site | < 0.001 | |||
Gastric GIST | 3 (20%) | 2 (13.3%) | 1 (6.7%) | |
Non-gastric GIST | 12 (80%) | 8 (53.3%) | 4 (26.7%) | |
Reason of surgery | 0.392 | |||
Tumor rupture | 8 (53.3%) | 4 (26.7%) | 4 (26.7%) | |
Intestinal obstruction | 5 (33.3%) | 4 (26.7%) | 1 (6.7%) | |
Gastrointestinal bleeding | 2 (13.3%) | 2 (13.3%) | 0 (0%) | |
Complication (Dindo–Clavien Classification) | 0.567 | |||
I | 9 (60%) | 7 (46.7%) | 2 (13.3%) | |
II | 4 (26.7%) | 3 (20%) | 1 (6.7%) | |
IIIa | 1 (6.7%) | 0 (0%) | 1 (6.7%) | |
IIIb | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
Length of stay (days) | 24.80 ± 9.34 | 25.60 ± 10.41 | 0.836 | |
Resection of organs | 2.70 ± 1.58 | 3.40 ± 1.34 | 0.898 | |
Organs invaded by GIST | 1.00 ± 0.47 | 1.60 ± 0.89 | 0.038 | |
Genetic mutation | 0.531 | |||
KIT exon 11 | 5 (33.3%) | 3 (20%) | 2 (13.3%) | |
KIT exon 9 | 3 (20%) | 3 (20%) | 0 (0%) | |
KIT exon 11 + 17 | 2 (13.3%) | 1 (6.7%) | 1 (6.7%) | |
Wild type | 2 (13.3%) | 1 (6.7%) | 1 (6.7%) | |
KIT exon 17 | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
KIT exon 11 + 13 | 1 (6.7%) | 0 (0%) | 1 (6.7%) | |
KIT exon 11 + PDGFRA | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
Location of metastases | 0.153 | |||
liver only | 2 (13.3%) | 1 (6.7%) | 1 (6.7%) | |
peritoneum only | 5 (33.3%) | 5 (33.3%) | 0 (0%) | |
both liver and peritoneum | 8 (53.3%) | 4 (26.7%) | 4 (26.7%) | |
TKI therapy after CRS | 0.497 | |||
Sunitinib | 4 (26.7%) | 3 (20%) | 1 (6.7%) | |
Imatinib + Sunitinib | 3 (20%) | 2 (13.3%) | 1 (6.7%) | |
Imatinib | 2 (13.3%) | 2 (13.3%) | 0 (0%) | |
Imatinib + Sunitinib + Dasatinib | 2 (13.3%) | 1 (6.7%) | 1 (6.7%) | |
Imatinib + Sunitinib + Regorafenib | 1 (6.7%) | 0 (0%) | 1 (6.7%) | |
Imatinib + Sunitinib + Ripretinib | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
Sunitinib + Regorafenib + Dasatinib | 1 (6.7%) | 0 (0%) | 1 (6.7%) | |
Imatinib + Dasatinib + Regorafenib | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
T Stage | 0.662 | |||
T1 | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
T2 | 0 (0%) | 0 (0%) | 0 (0%) | |
T3 | 4 (26.7%) | 3 (20%) | 1 (6.7%) | |
T4 | 10 (66.7%) | 6 (40%) | 4 (26.7%) | |
N Stage | ||||
N0 | 15 (100%) | 10 (66.7%) | 5 (33.3%) | |
N1 | 0 (0%) | 0 (0%) | 0 (0%) | |
Mitotic Rate | 1.000 | |||
Low (≤ 5/50HPF) | 6 (40%) | 4 (26.7%) | 2 (13.3%) | |
High (> 5/50HPF) | 9 (60%) | 6 (40%) | 3 (20%) | |
Prognostic Category | 0.654 | |||
1 | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
3b | 1 (6.7%) | 1 (6.7%) | 0 (0%) | |
6a | 4 (26.7%) | 3 (20%) | 1 (6.7%) | |
6b | 9 (60%) | 5 (33.3%) | 4 (26.7%) | |
Number of metastases | 0.171 | |||
≤ 5 | 3 (20%) | 3 (20%) | 0 (0%) | |
> 5 | 12 (80%) | 7 (46.7%) | 5 (33.3%) | |